Short Interest in Hemispherx BioPharma, Inc (HEB) Drops By 5.1%

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 508,727 shares, a decrease of 5.1% from the December 14th total of 536,330 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average trading volume of 357,145 shares, the short-interest ratio is currently 1.4 days.

HEB opened at $0.22 on Friday. Hemispherx BioPharma has a 12-month low of $0.15 and a 12-month high of $0.65.

Hemispherx BioPharma (NYSEAMERICAN:HEB) last posted its quarterly earnings results on Thursday, November 15th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter. The company had revenue of $0.04 million for the quarter.

COPYRIGHT VIOLATION NOTICE: “Short Interest in Hemispherx BioPharma, Inc (HEB) Drops By 5.1%” was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at

About Hemispherx BioPharma

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

Read More: How to find the components of the quick ratio

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with's FREE daily email newsletter.

Leave a Reply